表紙
市場調查報告書

乾癬:KOL (關鍵意見領袖) 分析

Psoriasis: KOL Insight [2018]

出版商 FirstWord 商品編碼 372760
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
如有價格方面的疑問請按下「詢問」鍵來信查詢
Back to Top
乾癬:KOL (關鍵意見領袖) 分析 Psoriasis: KOL Insight [2018]
出版日期: 2018年10月30日內容資訊: 英文
簡介

採納本報告提供乾癬的已上市藥物9種及開發階段的藥物10種,北美及歐洲的12名彙整由於關鍵意見領袖(KOL) 的各種見解。

已上市藥物

  • Humira (Adalimumab:Abbvie)
  • Enbrel (Etanercept:Amgen)
  • Benepali (Etanercept生技仿製藥:Biogen)
  • Flixabi (Infliximab生技仿製藥:Biogen)
  • Otezla (apremilast:Celgene)
  • Remsima/Inflectra (Infliximab生技仿製藥:Celltrion/Pfizer)
  • Taltz (ixekizumab:Eli Lilly)
  • Remicade (Infliximab:Merck & Co./Janssen)
  • Cosentyx (secukinumab:Novartis)

開發平台藥物

  • Cosentyx (secukinumab:Novartis)
  • Brodalumab (Amgen/AstraZeneca/Leo Pharma)
  • Risankizumab (BI 655066:Boehringer Ingelheim/AbbVie)
  • Piclidenoson (CF101:Can-Fite Biopharma)
  • Guselkumab (抗IL-23:Janssen/Morphosys)
  • Amiselimod (MT-1303:田邊三菱製藥/Biogen)
  • Xeljanz (Tofacitinib:Pfizer)
  • Etanercept 生技仿製藥 (GP2015 Sandoz Novartis)
  • Amilumab (MT-203:武田藥品工業/Amgen)
  • Cimzia (certolizumab pegol, UCB)

調查範例

  • 儘管許多治療藥但依然存在未滿足需求
    • KOL:特別想確認長期性的有效性和成本效益
    • 在未來的治療中其他的要求是?
  • 口服治療藥的特定的引進
    • KOL急於口服治療藥,不過尋求著口服給藥以上的東西
    • 開發平台藥物所需的事項是什麼?
  • 取得認可的生技仿製藥
    • 方便的償付上的決策也有讓競爭激化的可能性
    • 影響實際臨床現場的引進的因素是什麼?
  • 複數的IL標靶藥物的差異
    • 作為目前標準的Stelara (ustekinumab)的標的IL-12/23
    • 新的競爭對手把只以IL-17、IL-23為標的
    • KOL怎樣考慮這些下一代mAbs?
  • 新的通行證 Way的各種回饋
    • 初期候補藥到目前為止未成為標的的新途徑的利用
    • KOL期待的事項是什麼?
  • 安全性:主要的顧慮事項
    • 副作用和長期的安全性:新的治療藥的疑慮
    • 其內容和對KOL考慮利用的影響
  • 抬頭的個人化醫療
    • KOL由於目前治療藥的成果改善的與期待
    • 關於個人化醫療的可能性也很樂觀的
    • 這個趨勢形成的未來市場形象為何?

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Will biosimilar anti-TNFs prevent novel therapies from gaining traction?

As the use of biosimilar anti-TNFs continues to expand access , and lower the costs of, biologic therapies in the treatment for psoriasis, is there room for novel products, such as the anti-interleukin-(IL)-17 mAbs and next-generation anti-IL23 mAbs? What about recently approved products, such as Siliq/Kyntheum (brodalumab), and Tremfya (guselkumab; Janssen/MorphoSys)? Clinical and commercial differentiation will become critical and as the treatment landscape becomes more crowded. Learn how KOLs see the market evolving, how current products can protect market share, and how developers can differentiate their pipeline therapies in KOL Insight: Psoriasis. Twelve North American and European KOLs provide their insight on 11 marketed products and over 15 pipeline programmes.

Take a tour of the report now:

  • Methodology >
  • Research Objectives >
  • Questions Asked >
  • See the RCC therapies covered >
  • Find out who the 6 US and 6 European KOLs are >
  • Sample Pages >

Top Takeaways

  • What does the future hold for branded anti-TNFs? Anti-TNFs have the most long-term safety and efficacy data to substantiate their clinical use, with Humira (adalimumab; AbbVie) being the 'go-to' drug in this category for many KOLs. But with several anti-TNF biosimilars scooping up market share, and more on the way, what does the future hold for branded anti-TNFs?
  • What impact will next-generation anti-IL23 mAbs have on the treatment landscape? KOLs are impressed with anti-IL12/23 mAbs, such as Stelara (ustekinumab; Janssen Biotech), but can newer drugs in this category, such as Tremfya (guselkumab; Janssen Biotech/MorphoSys), move things on even further? And will the lack of long-term real-world safety data hamper near-term commercial dynamics?
  • How do KOLs describe the anti-IL17 mAbs? Safe, effective, quick? What concerns remain, particularly for products with chequered development histories and the emergence of rare adverse effects such as IBD and Crohn's disease? KOLs predict a future tussle between the anti-IL17 mAbs, but with which class of product?
  • Will payers influence the uptake of pipeline psoriasis drugs? If so, will this be based purely on cost and benefit of biosimilars, or do KOLs expect payers to look more closely at the data and allow patients to gain access to more effective treatments?
  • What have KOLs asked for from future treatments for psoriasis? Would KOLs prefer drugs that demonstrate long-term safety and disease remission, ones that allow for dosage flexibility and personalisation of treatment, or ones that are effective on the skin as well as joints?
  • Does the psoriasis treatment landscape have a differentiation problem? With many treatments available, and more on the way, what are KOLs most concerned about? What could help physicians make better treatment decisions so that patient care is optimised?

Quotes

"Certainly there's no direct comparison, but on paper it [brodalumab] is more effective versus placebo than compared to secukinumab and ixekizumab. It genuinely does have a different mode of action, so there is a reason to use it after secukinumab or ixekizumab has failed because it almost gives you a bit more justification, you're not just using another IL17 blocker."

EU Key Opinion Leader

"The more you switch the risk of immunogenicity will increase. We have no concerns with Enbrel biosimilars, but Infliximab and adalimumab have immunogenic potential, and I would not like to risk the [loss of] response of the patient. I will have no problems to initiate a drug from the beginning."

US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Taltz (ixekizumab; Eli Lilly)
  • Benepali (etanercept; Biogen/Samsung Bioepis)
  • Remsima (infliximab; Celltrion/Napp/Mundipharma)
  • Inflectra (infliximab; Pfizer/Celltrion)
  • Cosentyx (secukinumab; Novartis)
  • Otezla (apremilast; Celgene)
  • Stelara (ustekinumab; Janssen Biotech)
  • Humira (adalimumab; AbbVie)
  • Remicade (infliximab; Janssen Biotech/Merck & Co.)
  • Enbrel (etanercept; Amgen/Pfizer)

Pipeline Therapies

  • Siliq/Kyntheum (brodalumab; Leo Pharma/AstraZeneca)
  • Tremfya (guselkumab; Janssen Biotech/MorphoSys)
  • Amgevita/Amjevita (adalimumab; Amgen)
  • Erelzi (etanercept; Sandoz)
  • BI 695501 (adalimumab; Boehringer Ingelheim)
  • Tildrakizumab (Merck & Co./Sun Pharma)
  • Xeljanz (tofacitinib; Pfizer)
  • Imraldi (adalimumab; Biogen/Samsung Bioepis)
  • Cimzia (certolizumab pegol; UCB)
  • Risankizumab (Boehringer Ingelheim/AbbVie)
  • Piclidenoson (Can Fite Biopharma)
  • Mirikizumab (Eli Lilly)
  • Namilumab (Takeda)
  • Bimekizumab (UCB)
  • Various adalimumab and etanercept biosimilars (e.g. M923, MSB11022)

KOLs from North America

  • Steven R. Feldman. Professor of Dermatology, Professor of Pathology, Professor of Public Health Sciences - Social Science and Health Policy, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
  • Jeffrey M Weinberg. Associate Clinical Professor Dermatology, Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Alan Menter. Dermatologist and Program Director, Dermatology Residency Program, Baylor University Medical Center, Baylor University, Dallas, Texas.
  • Robert T Brodell. Professor and Chair, Department of Dermatology, and Professor and Interim Chair of the Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi.
  • Bryan Cho. Dermatologist and Geneticist, Department of Dermatology, University of California, San Francisco.
  • Craig Leonardi. Associate Clinical Professor of dermatology at St. Louis University Medical School, St. Louis, Missouri.

KOLs from Europe

  • Puig Sanz. Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau, an academic hospital which is affiliated with the Autonomous University of Barcelona.
  • Pablo Coto-Segura. Associate Professor of Dermatology, Hospital Universitario Central Asturias, Oviedo, Spain
  • Andrew Pink. Consultant Dermatologist, Guys and St. Thomas Hospital NHS Foundation Trust, London.
  • Richard Warren. Reader and Honorary Consultant Dermatologist, Division of Musculoskeletal & Dermatological Sciences, University of Manchester, UK
  • Odile Picard. Consultant at Saint Antoine Hospital in Paris, Professor of Dermatology at University of Saint-Antoine, France.
  • Anonymous German KOL. Professors and heads of a division with a specific focus on the treatment of inflammatory conditions, including psoriasis, at leading teaching hospitals in Germany.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Table of Contents

1. Executive summary

2. Research objectives and focus

  • 2.1 Research objectives
  • 2.2 Research focus

3. Overview of current biologic therapies in psoriasis treatment

  • 3.1 Key insights summary
    • 3.1.1 Anti-TNFs
    • 3.1.2 Anti-IL12/IL23s
    • 3.1.3 Anti-IL17s

4. Branded anti-TNFs

  • 4.1 Humira (adalimumab; AbbVie)
    • 4.1.1 Key insights summary
    • 4.1.2 Drug summary
  • 4.2 Enbrel (etanercept; Amgen)
    • 4.2.1 Key insights summary
    • 4.2.2 Drug summary
  • 4.3 Remicade (infliximab; Merck & Co./Janssen Biotech)
    • 4.3.1 Key insights summary
    • 4.3.2 Drug summary

5. Anti-TNF biosimilars

  • 5.1 Flixabi (infliximab; Merck & Co./Samsung Bioepis)
  • 5.2 Benepali (etanercept; Samsung Bioepis/Biogen)
  • 5.3 Remsima/Inflectra (infliximab; Celltrion/Hospira)
  • 5.4 Amgevita/Amjevita (adalimumab; Amgen)
  • 5.5 Erelzi (etanercept; Sandoz)
  • 5.6 Position of biosimilar anti-TNFs in psoriasis treatment paradigm
    • 5.6.1 Key insights summary
  • 5.7 Impact of anti-TNF biosimilars on the psoriasis treatment paradigm
    • 5.7.1 Key insights summary

6. Anti-IL12/23s

  • 6.1 Stelara (ustekinumab; Janssen Biotech)
    • 6.1.1 Key insights summary
    • 6.1.2 Drug summary

7. Anti-IL17s

  • 7.1 Cosentyx (secukinumab; Novartis)
    • 7.1.1 Key insights summary
    • 7.1.2 Drug summary
  • 7.2 Taltz (ixekizumab; Eli Lilly)
    • 7.2.1 Key insights summary
    • 7.2.2 Drug summary

8. PDE-IV inhibitors

  • 8.1 Otezla (apremilast; Celgene)
    • 8.1.1 Key insights summary
    • 8.1.2 Drug summary

9. Selected late-stage pipeline programmes

  • 9.1 Certolizumab pegol (Cimzia; UCB)
    • 9.1.1 Key insights summary
    • 9.1.2 Drug summary
  • 9.2 Tremfya (guselkumab; Janssen Biotech/MorphoSys)
    • 9.2.1 Key insights summary
    • 9.2.2 Drug summary
  • 9.3 Tildrakizumab (MK3222; Sun Pharma/Merck & Co./Almirall)
    • 9.3.1 Key insights summary
    • 9.3.2 Drug summary
  • 9.4 Risankizumab (BI655066; Boehringer Ingelheim/AbbVie)
    • 9.4.1 Key insights summary
    • 9.4.2 Drug summary
  • 9.5 Brodalumab (Siliq/Kyntheum; Valeant/Leo Pharma/AstraZeneca)
    • 9.5.1 Key insights summary
    • 9.5.2 Drug summary

10. Early- to mid-stage pipeline programmes

  • 10.1 JAK inhibitors
    • 10.1.1 Tofacitinib (Xeljanz; Pfizer)
  • 10.2 Adenosine A3 receptor (A3AR) antagonists
    • 10.2.1 Piclidenoson (CF101; Can-Fite Biopharma)
  • 10.3 Granulocyte macrophage colony-stimulating factor neutralisation
    • 10.3.1 Namilumab (MT-203; Takeda/Amgen)

11. Future of the psoriasis treatment paradigm

  • 11.1 Key insights summary
    • 11.1.1 Future of anti-TNFs
    • 11.1.2 Future of anti-IL12/23s
    • 11.1.3 Future of anti-IL17s
    • 11.1.4 KOL views on combination therapy

12. Evolution of the psoriasis treatment landscape

  • 12.1 Key insights summary

13. Appendix

  • 13.1 KOL Biographies
    • 13.1.1 US KOLs
    • 13.1.2 European KOLs
Back to Top